Axena Health and Mayo Clinic have partnered to integrate Mayo Clinic’s overactive bladder (OAB) educational content into Axena Health’s Leva Pelvic Health System. This collaboration aims to provide women with comprehensive, readily accessible information about OAB and urinary incontinence (UI) within a clinically proven treatment platform. Mayo Clinic has also made a financial investment in Axena Health to further support the development of women’s pelvic health initiatives.
This partnership is notable because it directly addresses a significant barrier to effective UI treatment: the lack of accessible and accurate information. By integrating trusted educational resources from a leading medical institution into a treatment platform already utilized by patients, the collaboration has the potential to significantly improve patient understanding and engagement in their own care. This can lead to better adherence to prescribed pelvic floor muscle training and potentially improved treatment outcomes. Furthermore, it normalizes discussions around UI, a condition often shrouded in stigma and misinformation.
The Leva Pelvic Health System combines an FDA-cleared device and a smartphone app to deliver personalized, at-home pelvic floor muscle training. The integration of Mayo Clinic’s OAB content will complement the app’s existing resources on UI and fecal incontinence. The content will be accessible to all Leva users starting in Spring 2025. The financial investment from Mayo Clinic will bolster Axena Health’s efforts to develop new pelvic health innovations, educational programs, and evidence-based treatments.
This collaboration signals a positive shift towards more holistic and patient-centered approaches in pelvic health. By combining a proven treatment system with high-quality educational resources, Axena Health and Mayo Clinic are creating a model for how technology and education can work together to empower patients and improve healthcare outcomes in an often-overlooked area of women’s health. This strategic partnership may also encourage further collaborations between medical device companies and leading healthcare institutions, driving innovation and improving access to effective pelvic health solutions for women.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
